Lara Maria Pasetto

Summary

Country: Italy

Publications

  1. ncbi Old and new drugs in systemic therapy of pancreatic cancer
    Lara Maria Pasetto
    Department of Medical Oncology, Azienda Ospedale Universita, Via Gattamelata 64, 35100 Padova, Italy
    Crit Rev Oncol Hematol 49:135-51. 2004
  2. ncbi Is acute dyspnea related to oxaliplatin administration?
    L M Pasetto
    Istituto Oncologico Veneto, Medical Oncology, Via Gattamelata 64, Padova 35128, Italy
    World J Gastroenterol 12:5907-8. 2006
  3. ncbi Stable disease in advanced colorectal cancer: therapeutic implications
    Lara Maria Pasetto
    Medical Oncology Division, Azienda Ospedale Universita, Padova, Italy
    Anticancer Res 26:511-22. 2006
  4. ncbi The development of platinum compounds and their possible combination
    Lara Maria Pasetto
    Medical Oncology Division, Azienda Ospedale Universita, Via Gattamelata 64, 35128 Padova, Italy
    Crit Rev Oncol Hematol 60:59-75. 2006
  5. ncbi Oxaliplatin-related neurotoxicity: how and why?
    Lara Maria Pasetto
    Medical Oncology Division, Azienda Ospedale Universita, Via Gattamelata 64, Padova, Italy
    Crit Rev Oncol Hematol 59:159-68. 2006
  6. ncbi The role of capecitabine in the treatment of colorectal cancer in the elderly
    Lara Maria Pasetto
    Medical Oncology Division, Azienda Ospedale Universita, 35128 Padova, Italy
    Anticancer Res 26:2381-6. 2006
  7. ncbi Rectal cancer neoadjuvant treatment in elderly patients
    Lara Maria Pasetto
    Medical Oncology Department, Istituto Oncologico Veneto, Padova, Italy
    Anticancer Res 26:3913-23. 2006
  8. ncbi Recent progress in target therapy in colorectal cancer
    Lara Maria Pasetto
    Istituto Oncologico Veneto, Medical Oncology, 35128 Padova
    Anticancer Res 26:3973-81. 2006
  9. ncbi Gemcitabine in advanced biliary tract cancers
    Lara Maria Pasetto
    Istituto Oncologico Veneto, Medical Oncology Division, Via Gattamelata 64, 35128 Padova, Italy
    Crit Rev Oncol Hematol 61:230-42. 2007
  10. ncbi Hepatic metastases of colorectal cancer: locoregional intra-arterial treatment
    Lara Maria Pasetto
    Istituto Oncologico Veneto Medical Oncology Department, Padova, Italy
    Anticancer Res 26:4785-92. 2006

Collaborators

Detail Information

Publications50

  1. ncbi Old and new drugs in systemic therapy of pancreatic cancer
    Lara Maria Pasetto
    Department of Medical Oncology, Azienda Ospedale Universita, Via Gattamelata 64, 35100 Padova, Italy
    Crit Rev Oncol Hematol 49:135-51. 2004
    ..The incidence of pancreatic cancer nearly equals its death rate (97%). Two-year survival is about 10%. Chemotherapy treatment is problematic because of the palliative and limited duration of response...
  2. ncbi Is acute dyspnea related to oxaliplatin administration?
    L M Pasetto
    Istituto Oncologico Veneto, Medical Oncology, Via Gattamelata 64, Padova 35128, Italy
    World J Gastroenterol 12:5907-8. 2006
    ..Antimicotic and antiviral drugs did not evidence any benefit. The antiviral therapy was stopped and high dose metilprednisolone was started. The patient died of pulmonary distress after 10 d...
  3. ncbi Stable disease in advanced colorectal cancer: therapeutic implications
    Lara Maria Pasetto
    Medical Oncology Division, Azienda Ospedale Universita, Padova, Italy
    Anticancer Res 26:511-22. 2006
    ....
  4. ncbi The development of platinum compounds and their possible combination
    Lara Maria Pasetto
    Medical Oncology Division, Azienda Ospedale Universita, Via Gattamelata 64, 35128 Padova, Italy
    Crit Rev Oncol Hematol 60:59-75. 2006
    ..This review analyses a part of these platinum compounds analyzed to date, their mechanism of action, resistance and the future trends in this sector...
  5. ncbi Oxaliplatin-related neurotoxicity: how and why?
    Lara Maria Pasetto
    Medical Oncology Division, Azienda Ospedale Universita, Via Gattamelata 64, Padova, Italy
    Crit Rev Oncol Hematol 59:159-68. 2006
    ..The aim of this review is to analyse the mechanism underlying induction of neurotoxicity and the possible treatments to prevent and to treat it...
  6. ncbi The role of capecitabine in the treatment of colorectal cancer in the elderly
    Lara Maria Pasetto
    Medical Oncology Division, Azienda Ospedale Universita, 35128 Padova, Italy
    Anticancer Res 26:2381-6. 2006
    ....
  7. ncbi Rectal cancer neoadjuvant treatment in elderly patients
    Lara Maria Pasetto
    Medical Oncology Department, Istituto Oncologico Veneto, Padova, Italy
    Anticancer Res 26:3913-23. 2006
    ..A secondary endpoint was to identify any specific comorbidity that affected either effectiveness or morbidity of treatment...
  8. ncbi Recent progress in target therapy in colorectal cancer
    Lara Maria Pasetto
    Istituto Oncologico Veneto, Medical Oncology, 35128 Padova
    Anticancer Res 26:3973-81. 2006
    ..All the most important data obtained through recent studies are discussed, emphasizing their mechanisms of action, safety profiles and clinical applications...
  9. ncbi Gemcitabine in advanced biliary tract cancers
    Lara Maria Pasetto
    Istituto Oncologico Veneto, Medical Oncology Division, Via Gattamelata 64, 35128 Padova, Italy
    Crit Rev Oncol Hematol 61:230-42. 2007
    ..Here we examine clinical trials designed for locally advanced and metastatic biliary tract cancer and review the existing data supporting palliative therapy with gemcitabine alone or in association with other drugs...
  10. ncbi Hepatic metastases of colorectal cancer: locoregional intra-arterial treatment
    Lara Maria Pasetto
    Istituto Oncologico Veneto Medical Oncology Department, Padova, Italy
    Anticancer Res 26:4785-92. 2006
    ..Aiming to evaluate a possible influence of HAI in these new treatments, the most important studies underlining the evolution of intrahepatic administration in recent years are reviewed...
  11. ncbi Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology units in Italy
    Lara Maria Pasetto
    Istituto Oncologico Veneto, IRCCS, Oncologia Medica 2, Padova, Italy
    Anticancer Res 27:3601, 3603-8. 2007
    ..The aim of this retrospective analysis was to evaluate the differences of 1-year treatment and chemotherapy related-toxicity in elderly colorectal cancer (CRC) patients in different Italian medical oncology units...
  12. ncbi Quality of life in elderly cancer patients
    Lara Maria Pasetto
    Istituto Oncologico Veneto, Medical Oncology Department, Via Gattamelata 64, 35128 Padova, Italy
    Eur J Cancer 43:1508-13. 2007
    ....
  13. ncbi Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis
    Lara Maria Pasetto
    Medical Oncology Department, Via Gattamelata 64, Istituto Oncologico Veneto, 35128 Padova, Italy
    Anticancer Res 27:1079-85. 2007
    ..The purpose of this study was to review the feasibility and outcome of multimodality treatment of rectal cancer patients metastatic at diagnosis...
  14. ncbi Colorectal cancer screening in elderly patients: when should be more useful?
    Lara Maria Pasetto
    Istituto Oncologico Veneto, IRCCS Medical Oncology 2nd, Via Gattamelata 64, 35128 Padova, Italy
    Cancer Treat Rev 33:528-32. 2007
    ....
  15. ncbi Determining therapeutic approaches in the elderly with rectal cancer
    Lara Maria Pasetto
    Medical Oncology 2nd, Istituto Oncologico Veneto, Padova, Italy
    Drugs Aging 24:781-90. 2007
    ..To evaluate the toxicity and feasibility of pelvic radiotherapy (RT) and/or surgery in elderly patients with locally advanced low-lying rectal cancer...
  16. ncbi Preoperative versus postoperative treatment for locally advanced rectal carcinoma
    Lara Maria Pasetto
    Azienda Ospedale Universita, Medical Oncology Division, Via Gattamelata 64, 35128 Padova, Italy
    Future Oncol 1:209-20. 2005
    ....
  17. ncbi Colorectal cancer adjuvant treatment in elderly patients
    Lara Maria Pasetto
    Divisione di Oncologia Medica Direzione, Via Gattamelata 64, Azienda Ospedale Universita, 35128 Padova, Italy
    Crit Rev Oncol Hematol 55:201-6. 2005
    ..This paper examines the factors pertinent to the small number of clinical trials designed for adjuvant colorectal cancer in the elderly...
  18. ncbi Preoperative assessment of elderly cancer patients
    Lara Maria Pasetto
    Istituto Oncologico Veneto, IRCCS Medical Oncology 2nd, Via Gattamelata 64, 35128 Padova, Italy
    Crit Rev Oncol Hematol 64:10-8. 2007
    ..Independent extraction has been performed by the authors using predefined criteria, including study quality indicators...
  19. ncbi Liver metastases of colorectal cancer: medical treatments
    Lara Maria Pasetto
    Department of Medical Oncology, Via Gattamelata 64, Azienda Ospedale Universita, 35128 Padova, Italy
    Anticancer Res 23:4245-56. 2003
    ....
  20. ncbi Common management of primary rectal carcinoma in patients with stage IV disease at the diagnosis
    Lara Maria Pasetto
    Department of Medical Oncology, Via Gattamelata 64, Azienda Ospedale Universita, 35128 Padova, Italy
    Anticancer Res 23:4999-5004. 2003
    ....
  21. ncbi Role of neoadjuvant treatment in cT3N0M0 rectal cancer
    Lara Maria Pasetto
    Istituto Oncologico Veneto, IRCCS, Oncologia Medica 2, Via Gattamelata 64, 35128 Padova, Italy
    Anticancer Res 28:4129-35. 2008
    ..i.) (+/- oxaliplatin) or bolus or capecitabine (an oral fluorpyrimidine). A secondary endpoint was to identify the local relapse rate and OS in those patients also receiving an adjuvant chemotherapy...
  22. ncbi Neoadjuvant chemoradiotherapy with 5-fluorouracil by bolus
    Lara Maria Pasetto
    Istituto Oncologico Veneto, IRCCS, Medical Oncology 2, Padova, Italy
    Anticancer Res 28:4095-100. 2008
    ..Since the presence of cardiomiopathy may contraindicate c.i. of 5-FU, an alternative regimen of 5-FU CT-RT was prospectively studied in these patients...
  23. ncbi Neoadjuvant treatment for locally advanced rectal carcinoma
    Lara Maria Pasetto
    Medical Oncology Division, Azienda Ospedale Universita, Via Gattamelata 64, 35128 Padova, Italy
    Crit Rev Oncol Hematol 52:61-71. 2004
    ..Patient enrollment into rigorous and well-conducted clinical trials will generate new information regarding investigational therapies and it will offer improved therapies for patients with this disease...
  24. ncbi Improved tolerability of chemotherapy in soft tissue sarcomas: old and new strategies
    Lara Maria Pasetto
    Department of Medical Oncology, Azienda Ospedaliera, Universita, Padova, Italy
    Expert Rev Anticancer Ther 3:167-78. 2003
    ....
  25. ncbi Is there a role for chemoradiotherapy in the treatment of pancreatic carcinoma?
    Lara Maria Pasetto
    Department of Medical Oncology, Via Gattamelata 64 Azienda Ospedale Università, 35108 Padova, Italy
    Anticancer Res 23:2805-13. 2003
    ....
  26. ncbi Adjuvant treatment for elderly patients with colon cancer. An observational study
    Lara Maria Pasetto
    Istituto Oncologico Veneto, IRCCS, Medical Oncology 2nd, Padova, Italy
    Anticancer Res 28:2513-8. 2008
    ..In this study we were interested in the pattern of adjuvant treatment and possible effects on survival among elderly patients...
  27. ncbi Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units
    Lara Maria Pasetto
    Oncologia Medical 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy
    Anticancer Res 28:1813-20. 2008
    ..In this paper, we highlight the pattern of palliative treatment and possible effects on survival among elderly patients...
  28. ncbi Rectal cancer adjuvant chemotherapy: when is more useful?
    Lara Maria Pasetto
    Oncologia Medical 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy
    Anticancer Res 28:1805-12. 2008
    ..A secondary end-point was to identify the possible influence of clinical TNM (cTNM) or pathological TNM (pTNM) on TTP and overall survival (OS)...
  29. ncbi FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases
    Lara Maria Pasetto
    UO of Medical Oncology, Via Gattamelata 64 Azienda Ospedaliera Università, 35128 Padova, Italy
    Anticancer Res 25:563-76. 2005
    ..For each drug, the cost/mg, the cost/mg/m2 and the cost/therapy (according to its duration) are evaluated according to the prices reported in the Italian Directory of Medicines and Manufacturers, 63rd Edition, November 2003...
  30. ncbi Treatment of stage IV colorectal carcinoma in elderly patients
    Lara Maria Pasetto
    Divisione di Oncologia Medica Direzione, Azienda Ospedale Universita, Via Gattamelata 64, 35128 Padova, Italy
    Crit Rev Oncol Hematol 54:145-55. 2005
    ..This paper examines the factors pertinent to the small number of clinical trials designed for metastatic colorectal cancer in this group of persons...
  31. ncbi Health-related quality of life outcomes in disease-free survivors of mid-low rectal cancer after curative surgery
    Salvatore Pucciarelli
    Department of Oncological and Surgical Sciences, Section of Clinica Chirurgica II, University of Padova, Policlinico, VI piano, Via Giustiniani, 2, 35128, Padova, Italy
    Ann Surg Oncol 15:1846-54. 2008
    ..The main objective of this study was to investigate health-related quality of life (HRQOL) in terms of symptoms and functional outcomes in disease-free survivors of rectal cancer...
  32. ncbi Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy
    Marco Agostini
    Clinica Chirurgica II, Department of Oncological and Surgical Sciences, Universita di Padova, Via Giustiniani 2, Padova, Italy
    Drugs Aging 25:531-9. 2008
    ..Increasing evidence suggests that common gene polymorphisms may influence the toxicity of various cytotoxic agents used in the treatment of cancer...
  33. ncbi FOLFOX4 in advanced colorectal cancer: a monoinstitutional experience
    Giorgia Boscolo
    Operative Unit of Medical Oncology, Istituto Oncologico Veneto, Padua, Italy
    Tumori 92:193-6. 2006
    ..CONCLUSIONS: The number of therapeutic regimens more than their type influenced the results...
  34. ncbi Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature
    Antonella Brunello
    Department of Medical Oncology 2, Istituto Oncologico Veneto I O V I R C C S, Padova, Italy
    Drugs Aging 24:967-73. 2007
    ..Thus, careful baseline evaluation of elderly patients and constant clinical observation during infusion, especially during the first course of therapy, are recommended to reduce the risk of severe CNS toxicity from ifosfamide...
  35. ncbi Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study
    Alba Ariela Brandes
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Padova, Italy
    Cancer 101:2079-85. 2004
    ..The aim of the current study was to evaluate the overall response rate, toxicity, and time to progression (TTP) with the use of standard PCV in this setting...
  36. ncbi Early diagnosis followed by front-line autologous peripheral blood stem cell transplantation for patients affected by POEMS syndrome
    Luca Laurenti
    Haematology Institute, Universita Cattolica del Sacro Cuore, Rome, Italy
    Leuk Res 32:1309-12. 2008
    ..In conclusion early diagnosis is crucial to obtain best response and improve clinical outcome...
  37. ncbi The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia
    Elena Rossi
    Institute of Hematology, Catholic University, Rome, Italy
    Thromb Haemost 99:1030-4. 2008
    ..7, 95%CI 0.5-1.0) in comparison with those with unknown inherited defect. These data suggest that patients with proximal DVT have different risks of symptomatic PE according to the type of inherited thrombophilia...
  38. ncbi Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium
    Ida Martinelli
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, Italy
    Thromb Haemost 87:791-5. 2002
    ..Among thrombophilic abnormalities, the prothrombin mutation was the weakest risk factor. Thrombosis occurred more frequently in puerperium than in pregnancy, whether or not thrombophilia was diagnosed...
  39. ncbi Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk
    Elena Rossi
    Thromb Haemost 98:695-7. 2007
  40. ncbi Psychological factors affecting oncology conditions
    Luigi Grassi
    Section of Psychiatry, Department of Medical Sciences of Communication and Behavior, University of Ferrara, Ferrara, Italy
    Adv Psychosom Med 28:57-71. 2007
    ..g. emotional repression and avoidance). The role of specific DCPR constructs in influencing the course of illness is also an area that should be investigated...
  41. ncbi Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies
    Giuseppe Leone
    Institute of Hematology and Institute of cardiology, Catholic University, Rome, Italy
    Curr Med Chem Cardiovasc Hematol Agents 2:311-26. 2004
    ....
  42. ncbi G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome
    Francesco Burzotta
    Institute of Cardiology, Catholic University, Rome, Italy
    Haematologica 89:1134-8. 2004
    ..The prognostic value of the G20210A prothrombin gene polymorphism in patients with a first acute coronary syndrome has not been previously assessed. We conducted a prospective study to investigate this issue...
  43. ncbi Diagnostic criteria for psychosomatic research and psychosocial variables in breast cancer patients
    Luigi Grassi
    Section of Psychiatry, Department of Medical Sciences of Communication and Behavior, University of Ferrara, Ferrara, Italy
    Psychosomatics 45:483-91. 2004
    ..The study indicates the usefulness of the application of the DCPR in breast cancer, although further research is needed to improve the feasibility and internal validity of DCPR constructs...
  44. ncbi Psychosocial morbidity and its correlates in cancer patients of the Mediterranean area: findings from the Southern European Psycho-Oncology Study
    Luigi Grassi
    Department of Behaviour and Communication, Section of Psychiatry, University of Ferrara and Department of Mental Health and General University S Anna Hospital, Corso Giovecca 203, 44100 Ferrara, Italy
    J Affect Disord 83:243-8. 2004
    ....
  45. ncbi Use of the diagnostic criteria for psychosomatic research in oncology
    Luigi Grassi
    Department of Medical Sciences of Communication and Behavior, Section of Psychiatry, University of Ferrara, Ferrara, Italy
    Psychother Psychosom 74:100-7. 2005
    ..The aims of the study were to compare the DSM-IV and the DCPR in their application to cancer patients...
  46. ncbi Analysis of MTHFR polymorphisms and P16 methylation and their correlation with clinical-biological features of multiple myeloma
    Patrizia Chiusolo
    Hematology Department, Universita Cattolica del Sacro Cuore, L go Gemelli 8, 00168, Rome, Italy
    Ann Hematol 85:474-7. 2006
    ..However, controversial data have been published regarding a protective role of variant alleles of MTHFR on MM...
  47. ncbi The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S
    Valerio De Stefano
    Institute of Hematology, Catholic University, Rome, Italy
    Haematologica 91:695-8. 2006
    ..9, 95% CI 1.0-3.9); the carriers of PC or PS deficiency had a marginal increase in risk (hazard ratio 1.4, 95% CI 0.9-2.2). In conclusion, patients with AT deficiency are potential candidates for long-term oral anticoagulation...
  48. ncbi Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura
    Luana Fianchi
    Ann Hematol 86:225-6. 2007
  49. ncbi Forced expression of RDH10 gene retards growth of HepG2 cells
    Elena Rossi
    Department of Biology and Genetics for Medical Sciences, University of Milan, via Viotti 3 5, Milan 20133, Italy
    Cancer Biol Ther 6:238-44. 2007
    ....
  50. ncbi Different circumstances of the first venous thromboembolism among younger or older heterozygous carriers of the G20210A polymorphism in the prothrombin gene
    Valerio De Stefano
    Institute of Hematology, Catholic University, Rome, Italy
    Haematologica 88:61-6. 2003
    ..The aim of this study was to determine the risk of spontaneous or secondary venous thromboembolism (VTE) among younger and older carriers of the G20210A prothrombin polymorphism...